EDGEWELL PERSONAL CARE COMPANY (EPC) Spending and interest coverage
- R&D / revenue · 12 months: Value 2.65%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.91%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value 0.26×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 2.65% | Research and development expense / revenue. Period ending 2026-06-30. $59.40M ÷ $2.24B × 100 ≈ 2.65% |
| Stock-based compensation / revenue · 12 months | 0.91% | Share-based compensation / revenue. Period ending 2026-06-30. $20.40M ÷ $2.24B × 100 ≈ 0.91% |
| Interest coverage · 12 months | 0.26× | Operating income ÷ reported interest expense. $17.90M ÷ $68.70M ≈ 0.26× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 59.40M USD | Research and Development Expense |
| Revenue | 2.24B USD | |
| Stock-based compensation | 20.40M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 17.90M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 68.70M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $59.40M | $2.24B | $20.40M | $17.90M | $68.70M | 2.65% | 0.91% | 0.26× | Reported |
| 2026-03-31 | $59.50M | $2.23B | $21.10M | $37.80M | $71.40M | 2.66% | 0.94% | 0.53× | Reported |
| 2025-12-31 | $58.00M | $2.23B | $21.80M | $68.40M | $73.70M | 2.60% | 0.98% | 0.93× | Reported |
| 2025-09-30 | $57.60M | $2.22B | $24.50M | $96.60M | $73.20M | 2.59% | 1.10% | 1.32× | Reported |
| 2025-06-30 | $58.10M | $2.20B | $24.90M | $153.30M | $75.90M | 2.64% | 1.13% | 2.02× | Reported |
| 2025-03-31 | $58.70M | $2.22B | $25.60M | $182.30M | $75.30M | 2.64% | 1.15% | 2.42× | Reported |
| 2024-12-31 | $59.00M | $2.24B | $25.60M | $193.50M | $75.50M | 2.63% | 1.14% | 2.56× | Reported |
| 2024-09-30 | $58.40M | $2.25B | $26.50M | $199.30M | $76.50M | 2.59% | 1.18% | 2.61× | Reported |
| 2024-06-30 | $58.00M | $2.27B | $28.10M | $231.00M | $77.70M | 2.55% | 1.24% | 2.97× | Reported |
| 2024-03-31 | $58.20M | $2.27B | $27.50M | $234.50M | $78.10M | 2.56% | 1.21% | 3.00× | Reported |
| 2023-12-31 | $58.40M | $2.27B | $28.00M | $221.20M | $78.40M | 2.57% | 1.23% | 2.82× | Reported |
| 2023-09-30 | $58.50M | $2.25B | $27.50M | $227.00M | $78.50M | 2.60% | 1.22% | 2.89× | Reported |
| 2023-06-30 | $58.00M | $2.25B | $25.20M | $230.90M | $77.90M | 2.57% | 1.12% | 2.96× | Reported |
| 2023-03-31 | $56.80M | $2.23B | $24.90M | $195.20M | $76.70M | 2.55% | 1.12% | 2.54× | Reported |
| 2022-12-31 | $56.10M | $2.18B | $24.80M | $180.70M | $74.00M | 2.58% | 1.14% | 2.44× | Reported |
| 2022-09-30 | $55.50M | $2.17B | $23.80M | $181.20M | $71.40M | 2.56% | 1.10% | 2.54× | Reported |
| 2022-06-30 | $55.30M | $2.18B | $26.10M | $186.60M | $70.10M | 2.54% | 1.20% | 2.66× | Reported |
| 2022-03-31 | $56.30M | $2.13B | $27.50M | $207.80M | $68.50M | 2.65% | 1.29% | 3.03× | Reported |
| 2021-12-31 | $56.90M | $2.10B | $27.50M | $229.00M | $67.80M | 2.71% | 1.31% | 3.38× | Reported |
| 2021-09-30 | $57.80M | $2.09B | $27.30M | $238.80M | $67.90M | 2.77% | 1.31% | 3.52× | Reported |
| 2021-06-30 | $57.80M | $2.03B | $23.70M | (m) | $68.60M | 2.84% | 1.17% | (m) | Reported |
| 2021-03-31 | $55.60M | $1.94B | $21.00M | (m) | $67.70M | 2.86% | 1.08% | (m) | Reported |
| 2020-12-31 | $55.20M | $1.95B | $19.60M | (m) | $64.30M | 2.84% | 1.01% | (m) | Reported |
| 2020-09-30 | $55.30M | $1.95B | $19.20M | (m) | $61.20M | 2.84% | 0.98% | (m) | Reported |
| 2020-06-30 | $54.10M | $1.99B | $19.10M | (m) | $58.30M | 2.72% | 0.96% | (m) | Reported |
| 2020-03-31 | $54.60M | $2.11B | $18.00M | (m) | $58.40M | 2.58% | 0.85% | (m) | Reported |
| 2019-12-31 | $54.70M | $2.14B | $17.80M | (m) | $60.90M | 2.56% | 0.83% | (m) | Reported |
| 2019-09-30 | $53.50M | $2.14B | $17.80M | (m) | $62.60M | 2.50% | 0.83% | (m) | Reported |
| 2019-06-30 | $54.10M | (m) | $16.80M | (m) | $63.50M | (m) | (m) | (m) | Reported |
| 2019-03-31 | $56.10M | (m) | $17.70M | (m) | $64.40M | (m) | (m) | (m) | Reported |
| 2018-12-31 | $57.60M | (m) | $17.10M | (m) | $66.20M | (m) | (m) | (m) | Reported |
| 2018-09-30 | $61.10M | (m) | $17.00M | (m) | $68.00M | (m) | (m) | (m) | Reported |
| 2018-06-30 | $63.90M | (m) | $19.60M | (m) | $69.40M | (m) | (m) | (m) | Reported |
| 2018-03-31 | $65.40M | (m) | $20.10M | (m) | $70.50M | (m) | (m) | (m) | Reported |
| 2017-12-31 | $67.40M | (m) | $21.30M | (m) | $69.60M | (m) | (m) | (m) | Reported |
| 2017-09-30 | $67.60M | (m) | $22.20M | (m) | $69.20M | (m) | (m) | (m) | Reported |
| 2017-06-30 | $71.90M | (m) | $22.20M | (m) | $70.30M | (m) | (m) | (m) | Reported |
| 2017-03-31 | $73.00M | (m) | $23.90M | (m) | $71.00M | (m) | (m) | (m) | Reported |
| 2016-12-31 | $72.20M | (m) | $24.90M | (m) | $71.50M | (m) | (m) | (m) | Reported |
| 2016-09-30 | $71.90M | (m) | $25.60M | (m) | $71.80M | (m) | (m) | (m) | Reported |
| 2016-06-30 | $72.70M | (m) | (m) | (m) | $70.20M | (m) | (m) | (m) | Reported |
| 2016-03-31 | $72.00M | (m) | (m) | (m) | $79.40M | (m) | (m) | (m) | Reported |
| 2015-12-31 | $71.30M | (m) | (m) | (m) | $89.70M | (m) | (m) | (m) | Reported |
| 2015-09-30 | $71.00M | (m) | (m) | (m) | $99.80M | (m) | (m) | (m) | Reported |
| 2015-06-30 | $94.60M | (m) | (m) | (m) | $117.70M | (m) | (m) | (m) | Reported |
| 2015-03-31 | $94.50M | (m) | (m) | (m) | $117.70M | (m) | (m) | (m) | Reported |
| 2014-12-31 | $94.90M | (m) | (m) | (m) | $120.10M | (m) | (m) | (m) | Reported |
| 2014-09-30 | $94.80M | (m) | (m) | (m) | $122.60M | (m) | (m) | (m) | Reported |
| 2014-06-30 | $93.20M | (m) | (m) | (m) | $125.10M | (m) | (m) | (m) | Reported |
| 2014-03-31 | $94.20M | (m) | (m) | (m) | $126.70M | (m) | (m) | (m) | Reported |
| 2013-12-31 | $96.30M | (m) | (m) | (m) | $128.20M | (m) | (m) | (m) | Reported |
| 2013-09-30 | $99.00M | (m) | (m) | (m) | $130.50M | (m) | (m) | (m) | Reported |
| 2013-06-30 | $104.20M | (m) | (m) | (m) | $132.20M | (m) | (m) | (m) | Reported |
| 2013-03-31 | $108.60M | (m) | (m) | (m) | $133.50M | (m) | (m) | (m) | Reported |
| 2012-12-31 | $111.50M | (m) | (m) | (m) | $130.90M | (m) | (m) | (m) | Reported |
| 2012-09-30 | $112.50M | (m) | (m) | (m) | $127.30M | (m) | (m) | (m) | Reported |
| 2012-06-30 | $112.70M | (m) | (m) | (m) | $127.40M | (m) | (m) | (m) | Reported |
| 2012-03-31 | $111.90M | (m) | (m) | (m) | $123.20M | (m) | (m) | (m) | Reported |
| 2011-12-31 | $110.50M | (m) | (m) | (m) | $122.10M | (m) | (m) | (m) | Reported |
| 2011-09-30 | $108.30M | (m) | (m) | (m) | $121.40M | (m) | (m) | (m) | Reported |
| 2011-06-30 | $106.10M | (m) | (m) | (m) | $118.40M | (m) | (m) | (m) | Reported |
| 2011-03-31 | $101.90M | (m) | (m) | (m) | $119.40M | (m) | (m) | (m) | Reported |
| 2010-12-31 | $99.10M | (m) | (m) | (m) | $122.60M | (m) | (m) | (m) | Reported |
| 2010-09-30 | $97.10M | (m) | (m) | (m) | $125.40M | (m) | (m) | (m) | Reported |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-09-30 | $90.50M | (m) | (m) | (m) | $144.70M | (m) | (m) | (m) | Reported |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-09-30 | $91.70M | (m) | (m) | (m) | $181.30M | (m) | (m) | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COTY INC. (COTY) | United States | $2.307B | -3.15 |
| SOLESENCE, INC. (SLSN) | United States | $0.058B | -25.13 |
| Axil Brands, Inc. (AXIL) | United States | $0.042B | 17.24 |
| UNITED GUARDIAN INC (UG) | United States | $0.034B | 13.30 |
| Caring Brands, Inc. (CABR) | United States | $0.013B | |
| BONK, INC. (BNKK) | United States | $0.011B | -0.14 |
| cbdMD, Inc. (YCBD) | United States | $0.005B | -2.59 |
| INTERPARFUMS INC (IPAR) | United States | $3.707B | 21.36 |
| e.l.f. Beauty, Inc. (ELF) | United States | $5.934B | |
| Kenvue Inc. (KVUE) | United States | $33.844B | 22.14 |